Successful Transport of Blood Samples with Small Drones
|
By LabMedica International staff writers Posted on 17 Aug 2015 |

Image: Preparation of clinical blood samples for test-flights by small drone. (1) Left: Custom-cut foam block. (2) Right: Placement of sealed foam lock in the bio-hazard bags as well as absorbent material for potential sample containment (Photos courtesy of Johns Hopkins Medicine and PLOS One).

Image: (3) Left: Placement of first bio-hazard bag inside the second bio-hazard bag. (4) Middle-right: Placement of double-wrapped payload in the fuselage (Photo courtesy of Johns Hopkins Medicine and PLOS One).

Image: (5) Left: Covered, secured, and labeled fuselage. (6) Right: Launch with hand toss (Photo courtesy of Johns Hopkins Medicine and PLOS One).
A proof-of-concept, initial study has shown that small unmanned aerial systems (UAS) could potentially be used to transport clinical blood specimens for diagnostics without damage to the specimens.
In a first rigorous examination published about the impact of drone transport on biological samples, a team of clinical researchers and engineers, led by Timothy Kien Amukele, MD, PhD, pathologist at Johns Hopkins University School of Medicine (Baltimore, MD, USA) and director of a collaboration with Makerere University in Uganda, found that results of common, routine tests on the blood samples were not affected by up to 40 minutes of sample-travel in hobby-sized drones. This could especially aid millions of people in developing nations where most tests are currently done by dedicated laboratories that can be scores of miles from remote clinics in rural and economically impoverished areas that lack, for example, good roads.
“Biological samples can be very sensitive and fragile,” said Dr. Amukele. That sensitivity makes even the pneumatic-tube systems used by many hospitals, for example, unsuitable for transporting blood for certain purposes. Of particular concern related to sample transport in drones is the sudden acceleration that marks the launch of the vehicle and the jostling when the drone lands on its belly. “Such movements could have destroyed blood cells or prompted blood to coagulate and I thought all kinds of blood tests might be affected, but our study shows they weren’t,” he added.
For the study, total of 6 blood samples were collected from each of 56 healthy adult volunteers at Johns Hopkins Hospital. Samples were driven to a flight site an hour’s drive from the hospital on days when the temperature was moderate. There, half the samples were held stationary (non-flight); the other half were packaged for protection during the in-flight environment and to prevent leakage, then loaded into a hand-launched fixed-wing drone and flown for periods of 6–38 minutes. Owing to Federal Aviation Administration (FAA) rules, the flights were conducted in an unpopulated area, kept below 100 meters and in the line-of-sight of the certified drone pilot.
Samples were driven back from the flight-field to the Johns Hopkins Hospital Core Laboratory, where 33 of the most common chemistry, hematology, and coagulation tests were performed (tests that together account for around 80% of all such tests performed), including for sodium, glucose, and red blood cell count.
Comparing lab results of the flown vs. non-flown samples from each volunteer showed that these flights essentially had no impact, although the precision of one blood test—for total carbon dioxide (the bicarbonate test)—did differ for some samples pairs. This may be because the blood sat for up to 8 hours before being tested, but whether the out-of-range results were due to this time lag or to the drone transport is unknown. Nevertheless, there were no consistent differences in results between the flown vs. non-flown blood.
“The ideal way to test that would be to fly the blood around immediately after drawing it, but neither the FAA nor Johns Hopkins would like drones flying around the hospital,” said Dr. Amukele.
The likely next step is a pilot study in Africa where clinics are sometimes 60 or more miles away from labs. “A drone could go 100 km in 40 minutes,” said Dr. Amukele, “They’re less expensive than motorcycles, are not subject to traffic delays, and the technology already exists for the drone to be programmed to “home” to certain GPS coordinates, like a carrier pigeon.”
Drones have already been tested as carriers of medicines to clinics in remote areas, but whether and how drones will be used to carry medicines and potentially infectious patient specimens over more populated areas will depend on laws and regulations.
The study, by Amukele TK, et al, was published July 29, 2015, in the journal PLOS One.
Related Links:
Johns Hopkins University School of Medicine
In a first rigorous examination published about the impact of drone transport on biological samples, a team of clinical researchers and engineers, led by Timothy Kien Amukele, MD, PhD, pathologist at Johns Hopkins University School of Medicine (Baltimore, MD, USA) and director of a collaboration with Makerere University in Uganda, found that results of common, routine tests on the blood samples were not affected by up to 40 minutes of sample-travel in hobby-sized drones. This could especially aid millions of people in developing nations where most tests are currently done by dedicated laboratories that can be scores of miles from remote clinics in rural and economically impoverished areas that lack, for example, good roads.
“Biological samples can be very sensitive and fragile,” said Dr. Amukele. That sensitivity makes even the pneumatic-tube systems used by many hospitals, for example, unsuitable for transporting blood for certain purposes. Of particular concern related to sample transport in drones is the sudden acceleration that marks the launch of the vehicle and the jostling when the drone lands on its belly. “Such movements could have destroyed blood cells or prompted blood to coagulate and I thought all kinds of blood tests might be affected, but our study shows they weren’t,” he added.
For the study, total of 6 blood samples were collected from each of 56 healthy adult volunteers at Johns Hopkins Hospital. Samples were driven to a flight site an hour’s drive from the hospital on days when the temperature was moderate. There, half the samples were held stationary (non-flight); the other half were packaged for protection during the in-flight environment and to prevent leakage, then loaded into a hand-launched fixed-wing drone and flown for periods of 6–38 minutes. Owing to Federal Aviation Administration (FAA) rules, the flights were conducted in an unpopulated area, kept below 100 meters and in the line-of-sight of the certified drone pilot.
Samples were driven back from the flight-field to the Johns Hopkins Hospital Core Laboratory, where 33 of the most common chemistry, hematology, and coagulation tests were performed (tests that together account for around 80% of all such tests performed), including for sodium, glucose, and red blood cell count.
Comparing lab results of the flown vs. non-flown samples from each volunteer showed that these flights essentially had no impact, although the precision of one blood test—for total carbon dioxide (the bicarbonate test)—did differ for some samples pairs. This may be because the blood sat for up to 8 hours before being tested, but whether the out-of-range results were due to this time lag or to the drone transport is unknown. Nevertheless, there were no consistent differences in results between the flown vs. non-flown blood.
“The ideal way to test that would be to fly the blood around immediately after drawing it, but neither the FAA nor Johns Hopkins would like drones flying around the hospital,” said Dr. Amukele.
The likely next step is a pilot study in Africa where clinics are sometimes 60 or more miles away from labs. “A drone could go 100 km in 40 minutes,” said Dr. Amukele, “They’re less expensive than motorcycles, are not subject to traffic delays, and the technology already exists for the drone to be programmed to “home” to certain GPS coordinates, like a carrier pigeon.”
Drones have already been tested as carriers of medicines to clinics in remote areas, but whether and how drones will be used to carry medicines and potentially infectious patient specimens over more populated areas will depend on laws and regulations.
The study, by Amukele TK, et al, was published July 29, 2015, in the journal PLOS One.
Related Links:
Johns Hopkins University School of Medicine
Latest Hematology News
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
Channels
Clinical Chemistry
view channel
Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
Genetic Testing Identifies High-Risk Patients with Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is a lifelong, unpredictable condition that can require advanced therapies or surgery. More than half a million people in the U.... Read more
Ancestry-Informed Genomics Advances Precision Cancer Prognosis
Predicting survival in common cancers remains imprecise despite widespread use of tumor sequencing to guide care. Outcome disparities among patient populations also persist, and the genomic drivers behind... Read more
New Blood Test Predicts Organ-Specific Disease and Mortality Years in Advance
Quantifying organ-specific aging remains a diagnostic challenge, even as age-related disorders drive morbidity and mortality worldwide. Chronological age poorly reflects the physiologic decline that predisposes... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreIndustry
view channel
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more




.jpg)



